Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has decided to discontinue producing Pulmicort (budesonide) 100 and 200µg/dose HFA pMDI (pressurised metered dose inhaler) because of complex technical manufacturing issues with respect to the device.
Subscribe to our email newsletter
The decision will be implemented with immediate effect.
However, AstraZeneca said that the patients can continue using the device with the 100 and 200µg/dose until their current supply is exhausted.
Pulmicort (budesonide) is an inhaled anti-inflammatory glucocorticosteroid used to initiate and maintain the treatment of bronchial asthma in infants, children and adults.
It is available in a range of formulations such as Pulmicort Turbuhaler (dry powder inhaler), Pulmicort pMDI (pressurised metered dose inhaler, CFC free), and Pulmicort Respules (suspension for nebulisation, and approved only in certain countries.
AstraZeneca Global Operations and IS executive vice president David Smith said that the time required to fully resolve the technical issues is highly uncertain, and the company was, therefore, committed to think of the patients’ best interests and advise them to find an alternative medication at the earliest.
Product-specific processes and components go into the making of Pulmicort pMDI in combinations which not used with any other AstraZeneca respiratory products.